Acumen Pharmaceuticals (ABOS) Competitors $2.36 -0.01 (-0.42%) (As of 10:46 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ABOS vs. PRTK, QNCX, OVID, CHMA, EPZM, GHRS, HUMA, ANNX, ABVX, and IGMSShould you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Paratek Pharmaceuticals (PRTK), Quince Therapeutics (QNCX), Ovid Therapeutics (OVID), Chiasma (CHMA), Epizyme (EPZM), GH Research (GHRS), Humacyte (HUMA), Annexon (ANNX), ABIVAX Société Anonyme (ABVX), and IGM Biosciences (IGMS). These companies are all part of the "medical" sector. Acumen Pharmaceuticals vs. Paratek Pharmaceuticals Quince Therapeutics Ovid Therapeutics Chiasma Epizyme GH Research Humacyte Annexon ABIVAX Société Anonyme IGM Biosciences Acumen Pharmaceuticals (NASDAQ:ABOS) and Paratek Pharmaceuticals (NASDAQ:PRTK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership. Do insiders and institutionals hold more shares of ABOS or PRTK? 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.6% of Paratek Pharmaceuticals shares are owned by institutional investors. 7.1% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 8.0% of Paratek Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor ABOS or PRTK? In the previous week, Acumen Pharmaceuticals had 7 more articles in the media than Paratek Pharmaceuticals. MarketBeat recorded 7 mentions for Acumen Pharmaceuticals and 0 mentions for Paratek Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.01 beat Paratek Pharmaceuticals' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Acumen Pharmaceuticals Neutral Paratek Pharmaceuticals Neutral Which has stronger earnings & valuation, ABOS or PRTK? Acumen Pharmaceuticals has higher earnings, but lower revenue than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcumen PharmaceuticalsN/AN/A-$52.37M-$1.38-1.71Paratek Pharmaceuticals$160.27M0.80-$63.57M-$1.10-2.03 Do analysts recommend ABOS or PRTK? Acumen Pharmaceuticals currently has a consensus price target of $9.00, suggesting a potential upside of 281.36%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Paratek Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Paratek Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, ABOS or PRTK? Acumen Pharmaceuticals has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Paratek Pharmaceuticals has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Does the MarketBeat Community prefer ABOS or PRTK? Paratek Pharmaceuticals received 408 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. However, 71.43% of users gave Acumen Pharmaceuticals an outperform vote while only 60.56% of users gave Paratek Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAcumen PharmaceuticalsOutperform Votes2571.43% Underperform Votes1028.57% Paratek PharmaceuticalsOutperform Votes43360.56% Underperform Votes28239.44% Is ABOS or PRTK more profitable? Acumen Pharmaceuticals has a net margin of 0.00% compared to Paratek Pharmaceuticals' net margin of -35.44%. Paratek Pharmaceuticals' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acumen PharmaceuticalsN/A -32.99% -27.99% Paratek Pharmaceuticals -35.44%N/A -40.05% SummaryAcumen Pharmaceuticals beats Paratek Pharmaceuticals on 12 of the 18 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABOS vs. The Competition Export to ExcelMetricAcumen PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$141.79M$2.95B$5.07B$8.80BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-1.7116.8789.5613.60Price / SalesN/A280.301,224.8087.40Price / CashN/A169.3839.4536.27Price / Book0.654.436.976.33Net Income-$52.37M-$41.63M$119.04M$225.93M7 Day Performance-9.58%-5.15%-1.78%-0.96%1 Month Performance-12.59%-6.91%-3.59%1.06%1 Year Performance0.85%25.64%31.64%26.59% Acumen Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABOSAcumen Pharmaceuticals2.6751 of 5 stars$2.36-0.4%$9.00+281.4%+0.4%$141.79MN/A-1.7151Analyst RevisionPRTKParatek Pharmaceuticals0.0195 of 5 stars$2.23+1.8%N/A+0.0%$127.82M$160.27M-2.03268High Trading VolumeQNCXQuince Therapeutics2.4971 of 5 stars$1.86+1.1%$8.50+357.0%+109.1%$81.84MN/A0.0060OVIDOvid Therapeutics4.4265 of 5 stars$1.03-1.4%$4.04+294.1%-68.5%$72.79M$390,000.00-2.2160Analyst RevisionNews CoverageCHMAChiasmaN/A$3.76flatN/A+0.0%$217.68M$1.11M-2.6385Analyst ForecastEPZMEpizymeN/A$1.47flatN/A+0.0%$247.44M$37.43M-0.85250GHRSGH Research1.8331 of 5 stars$10.76-1.7%$35.67+231.5%+77.2%$559.84MN/A0.0010Analyst ForecastNews CoverageHUMAHumacyte2.8902 of 5 stars$4.44+0.7%$11.00+147.7%+71.6%$558.82M$1.57M0.00150Insider TradeNews CoverageANNXAnnexon2.7832 of 5 stars$5.20+0.8%$15.80+203.8%+100.0%$554.27MN/A0.0060Analyst RevisionABVXABIVAX Société Anonyme3.0118 of 5 stars$8.69-1.9%$39.80+358.0%-19.6%$549.99MN/A0.0061IGMSIGM Biosciences4.7096 of 5 stars$9.17-6.1%$16.13+75.8%+63.3%$545.25M$2.13M0.00190 Related Companies and Tools Related Companies PRTK Competitors QNCX Competitors OVID Competitors CHMA Competitors EPZM Competitors GHRS Competitors HUMA Competitors ANNX Competitors ABVX Competitors IGMS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ABOS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
